Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000768796
Ethics application status
Approved
Date submitted
9/07/2013
Date registered
9/07/2013
Date last updated
9/07/2013
Type of registration
Retrospectively registered
Titles & IDs
Public title
The role of gluten on gastrointestinal symptoms and mental health in people with non-coeliac gluten sensitivity.
Query!
Scientific title
The role of wheat gluten in the genesis of gastrointestinal symptoms and mental health in patients with non-coeliac gluten sensitivity: Understanding the mechanisms of action.
Query!
Secondary ID [1]
282798
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-coeliac gluten sensitivity
289569
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
289898
289898
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Participants receive one of three dietary challenges consecutively for 3 days, followed by a minimum 3-day washout before crossing over to the next diet. Challenge food is supplemented with gluten (16g/day whole wheat gluten), whey (16g/day whey protein isolate) or not supplemented (control). All meals and snacks are supplied throughout the duration of the study and controlled for other potential inducers of symptoms (FODMAPs, dairy, food chemicals).
Dietary adherence will be assessed by entries into a tick-box diary and unused food is counted at the end of each dietary challenge. Participants are asked to document any additional foods consumed.
Query!
Intervention code [1]
287481
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
Challenge 3: Control (food not supplemented)
All meals and snacks provided.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
289958
0
The comparison of the change in the overall gastrointestinal symptom score measured using a visual analogue scale.
Query!
Assessment method [1]
289958
0
Query!
Timepoint [1]
289958
0
Daily on each dietary challenge
Query!
Secondary outcome [1]
303661
0
The comparison of the change in anxiety and depression scores measured using the State Trait Personality Inventory.
Query!
Assessment method [1]
303661
0
Query!
Timepoint [1]
303661
0
Day 3 of each dietary challenge
Query!
Eligibility
Key inclusion criteria
Aged >16 years of age, met Rome III criteria for IBS prior to implementation of a GFD, had currently well controlled gastrointestinal symptoms, and had been adherent to a GFD for at least the preceding six weeks. Celiac disease was excluded by either a normal duodenal biopsy (Marsh 0) performed at endoscopy while on a gluten containing diet and/or by the absence of the HLA-DQ2 and HLA-DQ8 haplotype.
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Other significant gastrointestinal disease (such as cirrhosis or inflammatory bowel disease); other clinically significant co-morbidity; intake of non-steroidal anti-inflammatory agents; use of systemic immunosuppressant medication; poorly controlled psychiatric disease; excessive alcohol intake; pregnancy; or inability to give written informed consent.
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/08/2011
Query!
Actual
24/08/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
29/06/2012
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
22
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
287575
0
Government body
Query!
Name [1]
287575
0
National Health and Medical Research Council (NHMRC)
Query!
Address [1]
287575
0
Level 1
16 Marcus Clarke Street
Canberra ACT 2601
Query!
Country [1]
287575
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Monash University
Query!
Address
Faculty Medicine, Nursing & Health Sciences
Eastern Health Clinical School, Box Hill Hospital
Level 2, 5 Arnold St, Box Hill VIC
3128
Query!
Country
Australia
Query!
Secondary sponsor category [1]
286325
0
None
Query!
Name [1]
286325
0
Query!
Address [1]
286325
0
Query!
Country [1]
286325
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289549
0
Eastern Health Research & Ethics
Query!
Ethics committee address [1]
289549
0
Eastern Health, Level 4, 5 Arnold St, Box Hill, Victoria 3128
Query!
Ethics committee country [1]
289549
0
Australia
Query!
Date submitted for ethics approval [1]
289549
0
Query!
Approval date [1]
289549
0
Query!
Ethics approval number [1]
289549
0
E52/1011
Query!
Summary
Brief summary
The purpose of this study is to examine the effect of gluten on gastrointestinal symptoms and mental health in those with NCGS. It is hypothesised that a major effect of gluten in those with NCGS is on mental health and not necessarily on GI symptoms.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
41286
0
Prof Peter Gibson
Query!
Address
41286
0
The Alfred
55 Commercial Road
Melbourne, VIC 3004
Query!
Country
41286
0
Australia
Query!
Phone
41286
0
+61 3 9076 3325
Query!
Fax
41286
0
Query!
Email
41286
0
[email protected]
Query!
Contact person for public queries
Name
41287
0
Simone Peters
Query!
Address
41287
0
The Alfred Centre
Block B, Level 6
99 Commercial Road
Melbourne, VIC 3004
Query!
Country
41287
0
Australia
Query!
Phone
41287
0
+61 3 9903 0262
Query!
Fax
41287
0
Query!
Email
41287
0
[email protected]
Query!
Contact person for scientific queries
Name
41288
0
Simone Peters
Query!
Address
41288
0
The Alfred Centre
Block B, Level 6
99 Commercial Road
Melbourne, VIC 3004
Query!
Country
41288
0
Australia
Query!
Phone
41288
0
+61 3 9903 0262
Query!
Fax
41288
0
Query!
Email
41288
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Dimensions AI
Randomised clinical trial: gluten may cause depression in subjects with non-coeliac gluten sensitivity – an exploratory clinical study
2014
https://doi.org/10.1111/apt.12730
Embase
Letter: progressive weakening of the concept that gluten has a detrimental effect on mental health and gut symptoms in the absence of coeliac disease.
2022
https://dx.doi.org/10.1111/apt.16963
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF